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Heart diseaseProteotoxicity refers to the detrimental effects of damaged/misfolded proteins on the cell. Cardiac muscle is
particularly susceptible to proteotoxicity because sustained and severe proteotoxic stress leads to cell death
and the cardiac muscle has very limited self-renewal capacity. The ubiquitin–proteasome system (UPS) and
the autophagic-lysosomal pathway (ALP) are two major pathways responsible for degradation of most cellular
proteins. Alterations of UPS and ALP functions are associated with the accumulation of proteotoxic species in
the heart, a key pathological feature of common forms of heart disease including idiopathic, ischemic, and
pressure-overloaded cardiomyopathies and a large subset of congestive heart failure. Emerging evidence
suggests that proteasome inhibition or impairment activates autophagy and conversely, acute ALP inhibition
may sometimes increase intrinsic proteasome peptidase activities but chronic ALP inhibition hinders UPS
performance in ubiquitinated protein degradation. The exact molecular basis on which the two degradative
pathways interact remains largely undeﬁned. Here we review current understanding of the roles of the UPS
and autophagy in the control of cardiac proteotoxicity, with a speciﬁc focus on the crosstalk between the
two pathways. This article is part of a Special Issue entitled: Autophagy and protein quality control in
cardiometabolic diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Protein homeostasis, or proteostasis, is maintained by the concerted
efforts from various competing, yet integrated, cellular processes that
control the synthesis, folding, trafﬁcking, posttranslationalmodiﬁcation,
assembly/disassembly, localization, and degradation of proteins in the
cell [1]. Obviously, proteostasis is essential for keeping normal functioning
of cells, tissues, and organs. Disruption of proteostasis can result in the
accumulation of unfolded, misfolded, or damaged proteins, endangering
the affected organelles and cells. These adverse effects of damaged orF, congestive heart failure; CHIP,
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uncontrolled or severe proteotoxicity can conceivably perturb a variety
of cellular processes, induce dysfunction of the cell and even lead to cell
death, and thereby cause functional changes at the tissue and the organ
levels.
Proteotoxicity is increasingly implicated in cardiac pathogenesis
[1,3], especially during the progression to congestive heart failure
(CHF) from at least a subset of primary heart diseases, such as familial
cardiomyopathies [4], ischemic heart disease [4,5], and hypertensive
cardiomyopathy [6–8]. A common pathological feature of these cardiac
conditions is the presence of increased ubiquitinated proteins and
aberrant protein aggregation in cardiomyocytes [9,10]. Protein quality
control (PQC) includes multi-layered mechanisms serving to minimize
the amount and toxicity of misfolded proteins in the cell. PQC is carried
out by molecular chaperones and targeted protein degradation [11].
The latter is primarily performed by the ubiquitin (Ub)–proteasome
system (UPS). The UPS degrades terminally misfolded proteins one by
one. More recently, the autophagic-lysosomal pathway (ALP) is also
found to play a role in removal of misfolded proteins primarily in the
aggregated form (Fig. 1) [12]. Hence, the UPS and the ALP represent
the ﬁnal line of defense against proteotoxicity. The UPS and the ALP
were identiﬁed and had long been regarded as two independent proteo-
lytic pathways with no point of intersection. However, connections
between these two systems have been suggested in the past decade,
especially by studies using non-cardiac cells [13–15]. A seminal study
Fig. 1.An illustration of protein quality control in the cell. Chaperones help fold nascent polypeptides, unfoldmisfolded proteins and refold them, and channel terminallymisfolded proteins
for degradation by the ubiquitin–proteasome system (UPS) or chaperone-mediated autophagy (CMA). When escaped from targeted degradation, misfolded proteins form aggregates via
hydrophobic interactions. Aggregated proteins canbe selectively targeted bymacroautophagy to, anddegraded by, the lysosome. (Adopted from Fig. 1 ofWang et al. [12], with permission.)
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that autophagy was activated to compensate for UPS impairment in a
histone deacetylase 6 (HDAC6) dependent manner, and that HDAC6
overexpression rescued UPS impairment induced neurodegeneration
in an autophagy dependent fashion [13]. A subsequent study indicates
that HDAC6 promotes autophagosome–lysosome fusion in ubiquitin-
mediated selective quality control autophagy [16]. In cardiac research,
recent studies have also uncovered evidence that alterations in the
UPS and the ALP have direct or indirect impact on one another in both
healthy and disease states [8,17–20]. This provides a new perspective
in our understanding of cardiac PQC and proteotoxicity.
This reviewwill examine recent evidence that supports a pathogenic
role of altered UPS and/or ALP function in cardiac proteotoxicity, with
an emphasis on the emerging interplay between the two proteolytic
pathways.
2. UPS dysfunction in cardiac proteotoxicity
TheUPS is theprincipal pathway for protein catabolism in eukaryotic
cells and is responsible for degradation of the vast majority of abnormal
proteins in the cell [11]. In general, UPS-mediated protein degradation
consists of two steps: ubiquitination of a target protein molecule and
degradation of the ubiquitinated protein by the proteasome complex
with release of free and reusable Ub. Ubiquitination is the process that
covalently attaches a Ub or a chain of Ubs to the target proteinmolecule.
It is a strictly regulated cascade of enzymatic reactions catalyzed by a Ub
activating enzyme (E1), Ub conjugating enzyme (E2), Ub ligase (E3),
and sometimes a Ub chain elongation factor (E4). Similar to other
protein modiﬁcations, ubiquitination is reversible. Removal of Ub
moieties by deubiquitinases (DUB) can rescue the target protein from
Ub-dependent degradation. The 26S proteasome, consisting of a proteo-
lytic core (ie, the 20S proteasome) and regulatory particles (the 19S or
the 11S proteasomes), mediates the degradation of polyubiquitinated
proteins. In mammals, there are also immunoproteasomes in which theconstitutive form of the three peptidase subunits (β1, β2, and β5) is
respectively replaced by an inducible or immune isoform (β1i, β2i, and
β5i). The immunoproteasome in non-immune cells can be induced by
viral infection and γ-interferon and is presumably more suitable for
generation of peptide fragments for antigen presentation [21]. In
UPS-mediated protein degradation, ubiquitination and proteasomal
degradation of a substrate is coupled via intra- and extra-proteasomal
Ub receptors (Fig. 2) [22].
As recently reviewed by Day [9], myocardial UPS dysfunction is
observed in human cardiomyopathies and CHF. Indicated by the
presence of increased ubiquitinated proteins and pre-amyloid oligo-
mers in explanted human hearts suffering from end-stage CHF from
hypertrophic or dilated cardiomyopathy [10], inadequate PQC and
resultant proteotoxicity are prevalent in human heart disease during
its progression to CHF [11]. The understanding of the pathophysio-
logical signiﬁcance of cardiac proteotoxicity has beenmostly derived
from experimental studies on desmin-related cardiomyopathy
(DRC) and, to a lesser extent, on myocardial ischemia/reperfusion
(I/R) injury. DRC is cardiac manifestation of desmin-related myopathy
and is caused by mutations in desmin, αB-crystallin (CryAB), or other
desmin ﬁlament-related genes. These genetic mutations give rise to
increased misfolded proteins, leading to the formation of desmin-
positive aberrant protein aggregates in myocytes [23]. Hence, it
represents a prototype of inherent cardiac proteinopathy. DRC is
not common in humans but animal models of DRC provide an excellent
platform for the investigation into proteotoxicity and for the search for
measures to reduce cardiac proteotoxicity. Myocardial I/R injury is seen
during both the revascularization treatment and the natural course of
ischemic heart disease (IHD). I/R injury is associated with pathogenic
increases in oxidized/damaged proteins; hence, it represents an
acquired and also common pathological process with increased
proteotoxic stress.
The determination of UPS functional status in a cell, tissue, or organ
is remarkably facilitated by the creation and employment of biologically
Fig. 2. An illustration of the ubiquitin–proteasome system-mediated proteolysis. A protein substrate molecule is ﬁrst covalently taggedwith a chain of ubiquitin (Ub) protein molecules, a
process known as ubiquitination. Ubiquitination is performed by a cascade of enzymatic reactions catalyzed sequentially by E1 (Ub activating enzyme), E2 (Ub conjugating enzyme), and
E3 (Ub ligase). The conjugated Ub can be removed from the substrate via a process known as deubiquitination, which counters ubiquitination and is performed by deubiquitinating
enzymes (DUBs). Ubiquitinated substrates may be directly recognized and bound by the 19S proteasome (19S), but often require extra-proteasomal Ub receptor proteins (i.e., UBA-UBL
proteins) to be delivered to, and degraded by, the 26S proteasome (26S). The 26S consists of a 20S proteasome (20S) and the 19S regulatory particle (19S) associated with one or both
ends of the 20S. (Adopted from Fig. 2 of Wang X and Terpstra EJ [22], with permission.)
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[24–26]. For example, GFPdgn (or GFPu), which is created by carboxyl
fusion of an enhanced green ﬂuorescence protein (GFP) with degron
CL1 [24], has been extensively used [4,5,27–32]. The introduction of
GFPdgn into a DRC mouse model induced by cardiac transgenic (tg)
overexpression of a 7-amino-acid (R172–E178) deletion mutant
desmin (D7-des), revealed amassive increase in cardiacGFPdgn protein
levels in D7-des tg mice compared with the D7-des Non-tg mice. There
were no discernible changes inGFPdgnmRNA levels [28], demonstrating
UPS functional insufﬁciency in D7-des tg hearts. Co-overexpression at a
similar level of wild type desmin (WT-des) did not affect cardiac GFPdgn
protein levels. Myocardial total ubiquitinated proteins were markedly
increased in D7-des, but not WT-des, tg mice, suggesting that the
insufﬁciency occurs at a post-ubiquitination step. Very interestingly,
myocardial proteasomal peptidase activities were not decreased but
rather signiﬁcantly increased in theD7-des tgmice [28]. Taken together,
these ﬁndings indicate the existence of proteasome functional insufﬁ-
ciency (PFI) in D7-des tg hearts. Almost exactly the same set of changes
was also observed in another tg mouse model of DRC created by cardiac
overexpression of a missense mutation (R120G) of CryAB (CryABR120G)
[27]. These studies provide the ﬁrst demonstration that expression of a
human disease-linked misfolded protein causes PFI in intact animals.
The CryABR120G tg mice display more distinguishable stages of disease
progression than the D7-des tg mice [33,34], allowing delineation of
the temporal relationship between PFI and other cardiac pathologies.
Cardiac PFI in CryABR120G mice is clearly detectable before other cardiac
pathologies (e.g., cardiac hypertrophy and dysfunction) become discern-
ible, suggesting a potential pathogenic role for PFI in DRC progression
[27]. Indeed, subsequent studies showed that enhancing proteasomal
function either genetically via overexpression of proteasome activator
28α (PA28α, an 11S proteasome subunit) or pharmacologically via
sildenaﬁl treatment, signiﬁcantly delayed DRC progression in the
CryABR120G tg mice [4,31]. This represents the ﬁrst demonstration that
PFI plays an essential role in abonaﬁdeproteinopathy and that improving
proteasome function could be a potentially effective therapeutic strategy
to treat proteinopathy.
In DRC mouse hearts, increases in the abundance of ubiquitinated
proteins remarkably co-exist with unchanged or even increased protea-
some peptidase activities [27,28]. This situation is also frequently
observed in the heart under many other pathological conditions, such
as pressure overload and myocardial infarction [35,36]. These suggest
the existence of an uncoupling, or inadequacy in the coupling, between
ubiquitination and proteasomal degradation during the progression
from a large subset of heart disease to CHF. Notably, this inadequacy
in coupling has not been appreciated and is rarely tackled in cardiacliterature. The Ub receptor subunits of the 19S proteasome can directly
recognize and bind the ubiquitinated proteins that come into contact
with the 26S proteasome, but for the remote substrates, the coupling
or the delivery of the ubiquitinated protein substrates to the proteasome
may require extra-proteasomal shuttling Ub receptors. These receptors
must be able to bind both ubiquitinated proteins and the 19S (Fig. 2)
[37]. The UBL-UBA family proteins, including Ubiquilin1 and the
mammalian homologues of Rad23 and Ddi1, are ideally suited to
serve as shuttling Ub receptors. They have a Ub-like (UBL) domain
at N-termini and Ub associated (UBA) domain(s) at C-termini. The
UBA binds poly-ubiquitinated proteins and the UBL can interact with
the 19S via Rpn10 or Rpn1 subunits [22]. Using the D7-des DRC model,
our laboratory found that myocardial protein levels of Ubiquilin1 were
markedly upregulated [22]. It will be very important to determine the
signiﬁcance and underlyingpathophysiology of the elevatedUb receptor
in DRC hearts.
In contrast to DRC, which is a rare disease, IHD is the most common
formof primary etiology leading to CHF. Reduction of peptidase activities
and accumulation of oxidized andubiquitinated proteins are observed in
ischemicmyocardium [38,39]. Ischemia and I/R-induced oxidative stress
results in oxidative modiﬁcation of several proteasome subunits and
impairs cardiac proteasomes [38,40,41]. Deﬁciency of some Ub ligases,
such as Muscle-speciﬁc RING-ﬁnger proteins and the carboxyl terminus
of Hsp70-interacting protein (CHIP), sensitizesmice to I/R injury [42,43].
Ischemic preconditioning (IPC) is the most robust cardioprotective
measure for subsequent ischemic injury. IPC preserves cardiac protea-
some function and this preservation plays an important role in IPC
cardioprotection. A major pathogenic role of PFI in acute myocardial
I/R injury has recently been established. Using the GFPdgn reporter
mice, Tian et al. have uncovered PFI in acute myocardial I/R injury
[5]. Li et al. developed the ﬁrst genetic animal model of proteasome
functional enhancement by cardiomyocyte-restricted tg overexpression
of PA28α. This novel model allowed the ﬁrst demonstration that
enhancement of proteasome function protects against I/R injury in
mice [4]. In a companion study, Li et al. showed that PA28α overexpres-
sion enhances proteasome function and facilitates the removal of
oxidized proteins in cultured cardiomyocytes [44]. Interestingly, several
earlier reports showed beneﬁcial effects from administration of protea-
some inhibitors on experimental myocardial I/R injury [45–47]. The
beneﬁt from systemic proteasome inhibition likely arises from its
anti-inﬂammatory effect on non-cardiomyocyte cells [47,48]. This
is because genetically induced cardiomyocyte-restricted moderate
inhibition of the proteasome exacerbates acute I/R injury in mice [5].
As exempliﬁed by its necessity in DRC and myocardial I/R injury,
PFI plays a major pathogenic role in cardiac proteotoxicity, where
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UPS impairment in turn leads to further accumulation of misfolded
proteins and promotes their aggregation, forming a vicious cycle
[49]. Individual and oligomeric misfolded proteins are highly active
and believed to be the toxic species that injure the cells, including
cardiomyocytes [10,50].
3. Autophagy protects against cardiac proteotoxicity
Autophagy is an intracellular lysosomal degradation process
by which unnecessary or defective cytoplasmic components are
delivered to, and degraded by, lysosomes. Based on the route by
which a substrate enters the lysosome, autophagy is classiﬁed into
three types: microautophagy, chaperone-mediated autophagy (CMA),
and macroautophagy. Among the three types, microautophagy is the
least understood and appears to be a non-selective process by which
cytoplasmicmaterial is engulfed by direct invagination of the lysosomal
membrane itself and subsequent budding of vesicles into the lysosomal
lumen. In CMA, a cytosolic protein molecule with a KFERQ or KFERQ-
like motif in its sequence is recognized by a cytosolic chaperone heat
shock cognate protein 70 (Hsc70) that delivers the substrate protein
molecule to a receptor formed by LAMP-2A at the lysosomalmembrane,
in which a multimeric protein complex is assembled and delivers the
substrate into the lumen of the lysosome [51]. Like the UPS, CMA is
also capable of targeted degradation of individual misfolded proteins
[52]. In macroautophagy, a double membrane vesicle sequestering
proteins, cytoplasmic materials, or even organelles is formed and then
fused with the lysosome for cargo degradation (Fig. 1). The functional
relationship among the three types of autophagy remains largely
undeﬁned but crosstalk among them may exist as CMA has been found
to be constitutively activated in cells with impaired macroautophagy
[53]. Microautophagy and CMA have rarely been studied in cardiac
pathogenesis but research into the involvement of macroautophagy
(hereafter referred to as autophagy) in cardiac physiology andpathology
has exploded in the past decade [54,55].
By selective degradation of aberrant protein aggregates and
defective organelles, autophagy plays an important role in quality
control of the cytoplasm. By genetic, biochemical, andmorphological
means, our laboratory has previously revealed that autophagy is signiﬁ-
cantly upregulated in mouse hearts or cultured cardiomyocytes that
overexpress DRC-linked mutant proteins [56]. This upregulation is
protective because autophagy inhibition by 3-methyladenine (3-MA)
or belcin1 haploinsufﬁciency induced more protein aggregation in
cardiomyocytes, and accelerated pathological remodeling andmortality
in CryABR120G-based DRC mice [57]. Despite the upregulation, the ALP
function appears to be insufﬁcient in cardiomyocytes expressing the
DRC-linked misfolded proteins. This notion is supported by reports
that in both cultured cardiomyocytes and transgenic mice, further
increasing autophagy by overexpression of Atg7 signiﬁcantly reduced
proteotoxicity induced by overexpression of CryABR120G[58,59].
The pathophysiological role of autophagy in myocardial ischemia
and I/R seems tobemore complicated. Earlier studies show that autoph-
agy activated by hypoxia protects themyocardium against injury during
myocardial ischemia [60,61]; however, autophagy activation can also
cause non-apoptotic cell death during reperfusion and prolonged
hypoxia [60,62]. Thus, it was concluded that autophagy was protective
during ischemia but detrimental during reperfusion to the heart. But
this was disputed by the reports that autophagy activation protected
against simulated I/R injury in cultured cardiomyocytes [63,64]. It should
be pointed out that many earlier studies considered the signs of in-
creased autophagosome as the primary indicator of autophagic activa-
tion, without assessing autophagic ﬂux. This could sometimes lead to
incorrect conclusions because increased abundance of autophagosomes
could be caused by impaired removal of the autophagosomes by the
lysosome, a scenario in which autophagic ﬂux is decreased rather than
increased. More recent studies show that autophagy is impaired in I/Rhearts and impaired autophagosome removal contributes to cardiomyo-
cyte death in I/R injury [65–67], suggesting that enhancing the ALP
can protect against I/R injury. In a large animal model of myocardial I/R
injury, Xie et al. have recently demonstrated that HDAC inhibition via
SAHA administered either before ischemia or at the initiation of
reperfusion can remarkably reduce myocardial I/R injury and this
cardioprotection is at least in part through induction of autophagic
ﬂux at the infarct border zone [68].
Taken together, ALP impairment or inadequacy is a pathogenic
factor in cardiac diseases with increased proteotoxic stress, such as
DRC and IHD, and increasing autophagic ﬂux may potentially be an
effective therapeutic strategy to treat these cardiac conditions.
4. Functional interactions of the UPS and autophagy
In general, the UPS degrades 80–90% of proteins including short-
lived, native, misfolded, or damaged proteins in the cell [69]. In
contrast, autophagy primarily degrades most long-lived proteins
that likely reside in the membrane structure of cellular organelles
or exist as aberrant protein aggregates. The UPS and autophagy were
generally assumed as completely parallel pathways and serving distinct
functions. However, emerging studies strongly suggest functional inter-
actions between the two degradation systems. The UPS and autophagy
appear to be concertedly regulated for maintaining cardiac proteostasis
in both healthy and disease states [1,3,17,18,56].
4.1. Co-activation of the UPS and autophagy upon proteotoxic stress
UPS activation and autophagic activation are notmutually exclusive.
In fact, they often co-exist in the cell to deal with proteotoxic stress.
As described earlier, an individual terminally misfolded protein is
ubiquitinated and the polyubiquitinated protein can be degraded
by the 26S proteasome. When misfolded proteins escaped from the
UPS surveillance, they tend to form aggregates which are inaccessible
by the proteasome, however, activate the ALP and are thereby degraded
by the lysosome. The co-activation of the UPS and autophagy is best
illustrated during endoplasmic reticulum (ER) stress and the unfolded
protein response (UPR).
Terminallymisfolded proteins in the ER lumen are retro-translocated
into the cytosol and immediately degraded upon the retro-translocation
via a process known as ER-associated degradation (ERAD). ERAD is
primarily performedby the ERmembrane-associatedUPS.More recently,
autophagy is also implicated in ERAD [70,71]. An abnormal increase of
misfolded proteins in the ER lumen (i.e., ER stress) triggers the UPR
which involves multiple signaling pathways to result in concerted
changes in transcriptional and translational programs so that general
protein synthesis is attenuated and the expression of ER resident
chaperones and the ERAD are promoted [72]. The UPR is apparently
intended by the cell to reestablish ER proteostasis but sustained ER
stress and associated UPR cause cell death [72]. Exposure to hypoxia
in hypoxia-sensitive rats, compared with hypoxia-tolerant ones,
induced higher expression of ER stress markers and a greater activation
of the proteasome, associated with elevated oxidized proteins in the
heart [73]. In an in vivo experiment, ER stress inducer tunicamycin pro-
moted oxidative stress leading to upregulated activation of autophagy
[74]. The arms of IRE1α/XBP1 and PERK/eIF2α of the UPR are respon-
sible for lipid conjugation of LC3 and polyglutamine-induced LC3 con-
version, respectively [71,75], thereby mediating the UPR-induced
activation of autophagy. Since the proteasome plays a pivotal role in
ERAD, proteasome inhibition can cause ER stress. Several studies have
also highlighted the importance of transcription factor ATF4 in the
upregulation of autophagy following proteasome inhibition [15,76].
These data suggest that ER stress or the UPR works as a key unifying
factor of the UPS and autophagy.
It is conceivable that autophagic removal of protein aggregates not
only eliminates the physical impact of the aggregates on the cell but
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on the UPS. This is because, as mentioned earlier, the intermediate
species of protein aggregates resulting from aberrant aggregation of
misfolded proteins impairs proteasome function [24,27,29].
4.2. Proteasome impairment or inhibition results in compensatory activation
of autophagy
It is well-established that activation of autophagy occurs in response
to genetic or pharmacological inhibition of the UPS. Using an autophagic
reporter (GFP-LC3) in both cultured cardiomyocytes and the heart of
transgenic mice, our laboratory has previously demonstrated that
pharmacologically induced proteasome inhibition activates autophagy
[17]. In cultured cardiomyocytes, silencing of Psmb7, the gene encoding
a catalytic subunit (β2) of the 20S proteasome which is responsible for
caspase-like activity of the proteasome, increased the expression of ER
stress markers and the number of LC3-marked vacuoles, suggesting
that genetic inhibition of the proteasome induces autophagy possibly
via triggering ER stress in cardiomyocytes [77]. The REGγ-proteasome
proteolytic system is a Ub-independent proteasome pathway. Under
physiological conditions, REGγ inhibits autophagy through association
with SirT1 [78], a deacetylase regulating autophagy and metabolism.
Mice deﬁcient of the proteasome activator REGγ exhibit increased
autophagic activity in the liver [78]. Moreover, depletion of extracellular
mutant 29 (Ecm29), an adaptor protein that binds to a subset of 26S
proteasomes, increased the amounts of LC3β and p62, two proteins
that mediate autophagy [79]. These ﬁndings indicate that impairment
of the proteasome induced by loss of proteasome regulatory or catalytic
subunit is capable of stimulating autophagy. Indeed, upregulation of p62
and increased autophagic ﬂuxwere found to co-exist in cardiomyocytes
of DRC mouse models in which cardiac PFI was detected [56]. However,
it remains to be tested whether PFI is the direct cause and if p62
mediates autophagic activation in DRC hearts.
Regarding the molecular mechanism underlying autophagy
activation in response to proteasome inhibition, the picture is not
clear at present butmany factors have been suggested to play amediating
role. In general, unfolded or misfolded proteins resulting from various
stresses are rapidly degraded by the UPS. Impaired proteasome function
causes accumulation and aggregation of ubiquitinated proteins, forming
aggregates of various sizes. With the help of microtubule-mediated
transportation, the aberrant protein aggregates relocate to the vicinity of
the microtubule organization center, forming large inclusion body-like
structures known as aggresomes [80]. Aggresomes are believed to pro-
mote the bulky degradation of its content by the ALP [81]. When DRC-
linked misfolded proteins are overexpressed in cardiomyocytes in vitro
or in vivo, aggresomes are indeed formed [10,56]. Autophagosomes
containing small electron-dense protein aggregates can be found in the
vicinity of aggresomes [56]; however, even when lysosomal degradation
is blocked, we failed to ﬁnd the autophagic vacuole that contains
something with the size of an aggresome, with electron microscopy.
Hence,we posit that smaller protein aggregates either being transported
to aggresomes or broken off the already formed aggresome, other than
the aggresome per se, are degraded by autophagy [82]. It appears that
proteasome inhibition causes formation of an entrapment zone (E-
zone) and promotes lysosome positioning around the aggresome,
thereby facilitating ALP-mediated degradation of the accumulated
abnormal proteins [83]. On the other hand, proteasomal impairment
results in ER stress and subsequent UPR [77,84]. ER stress triggers au-
tophagy through accelerating the assembly of the pre-autophagosomal
structure, autophagosome formation and transport to the vacuole in
yeast [85]. Furthermore, the BCL2 family protein MCL1 (myeloid cell
leukemia sequence 1) might also be involved in proteasome inhibition-
induced autophagic activation. MCL1 is degraded by proteasome and
plays an essential role in myocardial homeostasis and autophagy [86].
Loss of MCL1 in the heart leads to mitochondrial dysfunction, impaired
autophagy and development of heart failure [87]. Therefore, there is apossibility that the impairment or inhibition of the proteasome may
stabilize MCL1 proteins, resulting in autophagic activation.
Taken together, while multiple possible mechanisms may medi-
ate a compensatory activation of autophagy following proteasomal
inhibition in non-cardiac cells, these links remain to be established
in cardiomyocytes and the heart, particularly during increased
proteotoxic stress.
4.3. The impact of autophagy inhibition on UPS performance
Proteasomes are likely degraded through the ALP [88], raising a
possibility of that ALP inhibition may accumulate proteasomes, leading
to enhanced proteasomal activity. A few reported studies have examined
the effect of ALP inhibition onUPS function primarily in non-cardiac cells
or tissues but have yielded seemingly contradicting results. Korolchuk
et al. showed in cultured HeLa cells and mouse embryonic ﬁbroblasts
(MEF) that chronic pharmacological or genetic inhibition of autophagy
does not alter proteasome peptidase activities but rather, the resultant
p62 accumulation hinders the degradation of ubiquitinated substrates
by the proteasome and thereby reduces UPS performance [89]. How-
ever, Wang et al. recently reported that inhibition of autophagy
under nutrient-deﬁcient conditions in cultured human colon cancer
cells result in increased proteasomal peptidase activities and upreg-
ulated expression of the 20S proteasome β5 subunit (PSMB5) [90].
This study also showed that the abundance of two endogenous Ub-
independent substrates of the proteasome is decreased by ALP
inhibition, suggesting that ALP inhibition activates proteasomal
degradation of at least Ub-independent substrates [90]. Difference
in cell type and culturing conditions between the two studies may
contribute to the observed difference in ALP inhibition effects on
proteasome activities. Notably, even with increased proteasome
peptidase activities and perhaps enhanced degradation of endogenous
Ub-independent proteasome substrates, the study by Wang et al. does
not rule out the possibility that ALP inhibition decreases UPS perfor-
mance in degrading ubiquitinated proteins. Cathepsin D is a major lyso-
somal protease [91]. The ﬁrst study on the in vivo impact of lysosomal
malfunction on proteasome activities was reported by Qiao et al.[92],
showing that mice with germ-line knockout of the cathepsin D gene
displayed impaired autophagy and a delayed decrease in proteasome
peptidase activities in the brain. The proteasome functional deﬁcit
induced by the germ-line knockout of cathepsin D was not discernible
until postnatal day 25 and was not accompanied by altered protein
expression of proteasome subunits [92]. Taken together, these non-
cardiac studies seem to suggest that the impairment of UPS performance
by ALP inhibition is likely caused by factor(s) outside of the proteasome.
Cultured neonatal rat cardiomyocytes treated with 3-MA, an
inhibitor of the initiation step of macroautophagy, for 7 days showed
a signiﬁcant increase in proteasome chymotrypsin-like activities [8].
Cathepsin-L (CTSL) is also a lysosomal protease and is required for
autophagic ﬂux. A report by Sun et al. shows in cultured neonatal
mouse cardiomyocytes that CTSL deﬁciency does not discernibly alter
proteasome peptidase activity at baseline but signiﬁcantly promotes
the elevation of the proteasome peptidase activity induced by a cardiac
hypertrophy inducer phenylephrine; however, phenylephrine-induced
signiﬁcant increases in the protein degradation rate in the CTSL+/+
cardiomyocytes were not observed in CTSL−/− cells. Phenylephrine
induced a remarkably greater increase in the abundance of total
ubiquitinated proteins in CTSL−/− cardiomyocytes than in CTSL+/+
cardiomyocytes [93]. Using our UPS reporter (GFPdgn) mice, we
have recently observed that long-term, but not short-term, inhibition
of the ALP increased the level of GFPdgn proteins but not GFPdgn
mRNA in the heart, providing the ﬁrst in vivo evidence that ALP
malfunction impairs UPS performance in the heart. Our additional
experiments using neonatal rat cardiomyocyte cultures further reveal
that p62 plays an essential role in hindering UPS performance by ALP
inhibition [19].
193C. Wang, X. Wang / Biochimica et Biophysica Acta 1852 (2015) 188–1945. Conclusion and future directions
TheUPS and autophagy are two complementaryproteolytic pathways
required for maintaining intracellular proteostasis in cardiomyocytes.
They work synergistically or independently to monitor, prevent, and
minimize cardiac proteotoxicity. Functional insufﬁciency of the UPS and
the ALP likely both contribute to the pathogenesis of heart disease with
increased proteotoxicity; accordingly, improved UPS performance and
enhanced autophagy can both ameliorate cardiac proteotoxicity.
Proteasome inhibition or PFI results in a compensatory activation of
the ALP but the underlying molecular mechanism remains to be investi-
gated. Conversely, long term ALP impairment or inhibition appears to
hinder UPS performance, in which accumulated Ub binding proteins
(e.g., p62) may be the culprit. Hence, it will be important to determine
whether inadequate lysosomal function is a potential indirect cause of
UPS insufﬁciency in cardiac proteinopathy. Similarly, the role of p62 in
cardiac PQC and proteotoxicity warrants further investigation. A better
understanding of the molecular regulation on the functional interaction
between the UPS and the ALP is expected to shine new light on the
development of more concerted and effective strategies to harness the
twomain proteolytic pathways to combat proteotoxicity-related cardiac
diseases.
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